<DOC>
	<DOCNO>NCT01709513</DOCNO>
	<brief_summary>This randomize , double-blind , double-dummy , active-controlled , parallel-group , multi-national , multi-center study compare alirocumab ( REGN727/SAR236553 ) versus ezetimibe participant primary hypercholesterolemia moderate , high , high CV risk , intolerant statin . An atorvastatin arm add determine population select study truly statin intolerant population assess skeletal muscle-related adverse event .</brief_summary>
	<brief_title>Study Alirocumab ( REGN727/SAR236553 ) Patients With Primary Hypercholesterolemia Moderate , High , Very High Cardiovascular ( CV ) Risk , Who Are Intolerant Statins ( ODYSSEY ALTERNATIVE )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion : 1 . Patients primary hypercholesterolemia [ Heterozygous Familial Hypercholesterolemia ( heFH ) nonFH ] moderate , high high CV risk history statin intolerance 2 . Provide sign informed consent Exclusion : 1 . Calculated serum LDLC &lt; 70 mg/dL ( 1.81 mmol/L ) high CV risk screen visit 2 . Calculated serum LDLC &lt; 100 mg/dL ( 2.59 mmol/L ) high moderate CV risk screen visit 3 . A 10year fatal cardiovascular disease risk score &lt; 1 % screen visit ( The inclusion/ exclusion criterion provide intend contain consideration relevant patient 's potential participation clinical trial ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>